Figure 2 | Scientific Reports

Figure 2

From: A screen of FDA-approved drugs identifies inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3)

Figure 2

Dose dependent inhibition of PRL family members with FDA-approved drugs. Dose response curves showing DiFMUP phosphatase activity of PRL-3 when treated with doses ranging between 1 nM and 100 µM of each drug. Inhibition of PRL-3 phosphatase activity by the broad PRL family inhibitors are shown, and drugs are subdivided into those with (a) high IC50 values and (b) low IC50 values. A subset of compounds preferentially inhibited PRL-3, including (c) Bardoxolone and (d) Eltromobag. All assays utilized a final protein concentration of 2.5 µM with DiFMUP concentration at the KM of the protein, and were run in technical duplicates in three independent experiments. Data represent mean phosphatase activity and error bars represent standard deviation between assays. * p < 0.01 comparing PRL-3 phosphatase activity to that of PRL-1 and PRL-2 at the indicated drug dose, using a two-way ANOVA with Dunnet’s correction.

Back to article page